Papageorgiou General Hospital
9
1
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
22.2%
2 terminated/withdrawn out of 9 trials
71.4%
-15.1% vs industry average
56%
5 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Corneal Biomechanics, Optical Properties and Anterior Segment Structural Features in Patients With Pseudoexfoliation
Role: collaborator
Evaluation of Bone Metabolism in Children and Adolescents With Familial Mediterranean Fever
Role: collaborator
Resting Energy Needs in Brain Dead Patients (reSting EneRgy nEeds iN brAin DEad Patients)
Role: collaborator
Periodic Versus Continuous IV Iron Supplementation in HD Patients
Role: lead
The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density
Role: lead
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Role: lead
The Prevalence of Osteoporosis in Hemodialysis Patients
Role: lead
Changes in Iron Markers Following Iron Loading in Hemodialysis Patients
Role: lead
Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism
Role: lead
All 9 trials loaded